Tumor Biology

, Volume 35, Issue 8, pp 8201–8208 | Cite as

S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials

  • Dan-Hong Li
  • Zhen-Kui Pan
  • Feng Ye
  • Han-Xiang An
  • Jing-Xun Wu
Research Article


To compare the efficacy, prognosis, and toxicity of S-1-based with fluorouracil (5-FU)-based chemotherapy in patients with advanced gastric cancer (AGC) as first-line treatment, we performed this meta-analysis of all eligible randomized controlled trials (RCTs). A comprehensive literature search of electronic databases (up to February 20, 2014) was performed. Additionally, abstracts presented at the American Society of Clinical Oncology (ASCO) conferences held between January 2000 and February 2014 were searched to identify relevant trials. Overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), and grade 3 or 4 toxicities were analyzed. Six RCTs with 2,264 patients of AGC were included. Meta-analysis demonstrated that S-1-based therapy was associated with better OS compared with 5-FU-based therapy (hazard ratio (HR) = 0.80, 95 % confidence interval (CI) 0.80–0.99, P = 0.03). Pooled estimate has showed the trend of superiority of S-1-based therapy in the aspect of ORR (odds ratio (OR) = 1.55, 95 % CI 0.87–2.77, P = 0.14) and TTF (HR = 0.73, 95 % CI 0.53–1.00, P = 0.05), but the difference was not significant. The incidence of toxicities of 5-FU-based regimens was significantly higher for thrombocytopenia (OR = 0.60, 95 % CI 0.42–0.88, P = 0.008) and stomatitis (OR = 0.22, 0, 95 % CI 0.05–0.9, P = 0.03). Based on the published studies, S-1-based therapy was superior to 5-FU-based therapy in OS and safety profile as first-line treatment in AGC. It was prone to improving ORR and TTF, though the difference was not significant. More high-quality randomized controlled trials should be performed to provide more information in comparing these two regimens.


Meta-analysis Advanced gastric cancer S-1 5-FU 


Conflicts of interest



  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5(2):189–90.PubMedGoogle Scholar
  3. 3.
    Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(3):587–91.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, et al. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anti-Cancer Drugs. 1999;10(8):729–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, et al. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study. Onkologie. 2002;25(3):255–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21(1):54–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Ajani JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. Cancer J Sci Am. 1999;5(2):112–4.PubMedGoogle Scholar
  8. 8.
    Bugat R. Irinotecan in the treatment of gastric cancer. Ann Oncol. 2003;14 Suppl 2:ii37–40.PubMedGoogle Scholar
  9. 9.
    Cascinu S, Galizia E, Labianca R, Ferrau F, Pucci F, Silva RR et al. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer chemotherapy and pharmacology. 2011;68(1):37–43.Google Scholar
  10. 10.
    Einzig AI, Lipsitz S, Wiernik PH, Benson 3rd AB. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Investig New Drugs. 1995;13(3):223–7.CrossRefGoogle Scholar
  11. 11.
    Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer. 1994;70(2):380–3.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Taal BG, Teller FG, ten Bokkel Huinink WW, Boot H, Beijnen JH, Dubbelman R. Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol. 1994;5(1):90–2.PubMedGoogle Scholar
  13. 13.
    Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs. 1996;7(5):548–57.PubMedCrossRefGoogle Scholar
  14. 14.
    Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58(3):191–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34(11):1715–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed). 2009;339:b2700.CrossRefGoogle Scholar
  17. 17.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed. 2009;339:b2535.Google Scholar
  18. 18.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRefGoogle Scholar
  19. 19.
    Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–53.Google Scholar
  20. 20.
    Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10(11):1063–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Huang D, Ba Y, Xiong J, Xu N, Yan Z, Zhuang Z et al. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer. 2013;49(14):2995–3002.Google Scholar
  22. 22.
    Jin M, Lu H, Li J, Shen L, Chen Z, Shi Y, et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. J Clin Oncol. 2008;26:4533.CrossRefGoogle Scholar
  23. 23.
    Nishikawa K, Morita S, Matsui T, Kobayashi M, Takeuchi Y, Takahashi I et al. A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer. 2012;15(4):363–9.Google Scholar
  24. 24.
    Rui-hua X, Guo-ping S, Hui-shan L, Liu Yun P, Jian-ming X, Mei-zuo Z, et al. A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2013;31:4025.Google Scholar
  25. 25.
    Huang J, Cao Y, Wu L, Liao C, He Y, Gao F. S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis. Medical oncology (Northwood, London, England). 2011;28(4):1004–11.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Dan-Hong Li
    • 1
  • Zhen-Kui Pan
    • 2
  • Feng Ye
    • 3
  • Han-Xiang An
    • 3
  • Jing-Xun Wu
    • 3
  1. 1.Obstetrics, Xiamen Maternity and Child Health Care HospitalXiamenPeople’s Republic of China
  2. 2.Department of OncologyQingdao Municipal HospitalQingdaoPeople’s Republic of China
  3. 3.Department of Medical OncologyThe First Affiliated Hospital of Xiamen UniversityXiamenPeople’s Republic of China

Personalised recommendations